Payment overview · 2025
General Payments
$454.22
18 reported records · 9 companies
Healthcare provider profile · identity verified
Christopher Joseph Achee, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · JENNINGS, LA · NPI 1710947205
Verified facts
What the public records show
CMS Open Payments records show Christopher Joseph Achee, M.D. received $454.22 in general payments during 2025 across 18 reported records.
Ardelyx, Inc. accounted for 30.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Ubrelvy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $136.37 | 30.0% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $70.29 | 15.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.58 | 11.6% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $46.41 | 10.2% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $39.09 | 8.6% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $37.08 | 8.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.00 | 6.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $23.67 | 5.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.73 | 4.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $454.22 | 18 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $136.37 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $70.29 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $52.58 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.58 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $46.41 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $39.09 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.00 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| ROTATEQ Normalized: rotateq |
Biological | Merck Sharp & Dohme LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 141 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
127 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
141 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
76 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 74 |
| Atorvastatin Calcium | Atorvastatin Calcium | 241 | 61 |
| Alprazolam | Alprazolam | 192 | 21 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 44 |
| Amlodipine Besylate | Amlodipine Besylate | 168 | 44 |
| Lisinopril | Lisinopril | 167 | 31 |
| Mounjaro | Tirzepatide | 141 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 37 |
| Jardiance | Empagliflozin | 127 | 18 |
| Metformin Hcl | Metformin Hcl | 121 | 23 |
| Losartan Potassium | Losartan Potassium | 118 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 112 | 26 |
| Gabapentin | Gabapentin | 111 | 21 |
| Valsartan | Valsartan | 109 | 24 |
| Potassium Chloride | Potassium Chloride | 90 | 17 |
| Metoprolol Succinate | Metoprolol Succinate | 85 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 82 | 17 |
| Prednisone | Prednisone | 82 | 48 |
| Mirtazapine | Mirtazapine | 81 | 11 |
| Eliquis | Apixaban | 76 | suppressed |
| Omeprazole | Omeprazole | 76 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 73 | 16 |
| Chlorthalidone | Chlorthalidone | 72 | 18 |
| Simvastatin | Simvastatin | 69 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 18 |
| Meloxicam | Meloxicam | 61 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 60 | 17 |
| Carvedilol | Carvedilol | 59 | 13 |
| Tamsulosin Hcl | Tamsulosin Hcl | 59 | 18 |
| Torsemide | Torsemide | 56 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 51 | 12 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Allopurinol | Allopurinol | 48 | 13 |
| Ozempic | Semaglutide | 48 | suppressed |
| Cefdinir | Cefdinir | 46 | 35 |
| Metformin Hcl Er | Metformin Hcl | 46 | 11 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Furosemide | Furosemide | 45 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 45 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 17 |
| Ezetimibe | Ezetimibe | 40 | 13 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Levofloxacin | Levofloxacin | 38 | 34 |
| Sertraline Hcl | Sertraline Hcl | 37 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 32 | 16 |
| Clonazepam | Clonazepam | 32 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Pregabalin | Pregabalin | 30 | suppressed |
| Finasteride | Finasteride | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 29 | suppressed |
| Temazepam | Temazepam | 28 | suppressed |
| Fluconazole | Fluconazole | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 26 | 11 |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 23 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 22 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Repatha Pushtronex | Evolocumab | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Famotidine | Famotidine | 16 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Levetiracetam | Levetiracetam | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 13 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 13 | suppressed |
| Victoza 2-Pak | Liraglutide | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Ubrelvy | Ubrogepant | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $454.22 · 18 records | Ardelyx, Inc. | Auvelity, CAPLYTA, CAPVAXIVE, GARDASIL 9, IBSRELA, MOUNJARO, NURTEC ODT, QULIPTA, ROTATEQ, SUBLOCADE, The Cologuard Plus Collection Kit, UBRELVY, VAQTA, VAXELIS, ZAVZPRET, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error